IBCL - 549
Two-Year Rituximab Maintenance vs Observation After First-Line Treatment With Bendamustine Plus Rituximab (B-R) in Patients With Waldenström’s Macroglobulinemia: Results of a Prospective, Randomized Multicenter Phase 3 Study (StiL NHL7-2008 MAINTAIN Trial
Mathias Rummel
Poster Presenter: Mathias Rummel